Literature DB >> 34384824

Simple and rapid high-throughput assay to identify HSV-1 ICP0 transactivation inhibitors.

Cindy Y Ly1, Chunmiao Yu1, Peter R McDonald2, Anuradha Roy2, David K Johnson3, David J Davido4.   

Abstract

Herpes simplex virus 1 (HSV-1) is a ubiquitous virus that results in lifelong infections due to its ability to cycle between lytic replication and latency. As an obligate intracellular pathogen, HSV-1 exploits host cellular factors to replicate and aid in its life cycle. HSV-1 expresses infected cell protein 0 (ICP0), an immediate-early regulator, to stimulate the transcription of all classes of viral genes via its E3 ubiquitin ligase activity. Here we report an automated, inexpensive, and rapid high-throughput approach to examine the effects of small molecule compounds on ICP0 transactivator function in cells. Two HSV-1 reporter viruses, KOS6β (wt) and dlx3.1-6β (ICP0-null mutant), were used to monitor ICP0 transactivation activity through the HSV-1 ICP6 promoter:lacz expression cassette. A ≥10-fold difference in β-galactosidase activity was observed in cells infected with KOS6β compared to dlx3.1-6β, demonstrating that ICP0 potently transactivates the ICP6 promoter. We established the robustness and reproducibility with a Z'-factor score of ≥0.69, an important criterium for high-throughput analyses. Approximately 19,000 structurally diverse compounds were screened and 76 potential inhibitors of the HSV-1 transactivator ICP0 were identified. We expect this assay will aid in the discovery of novel inhibitors and tools against HSV-1 ICP0. Using well-annotated compounds could identify potential novel factors and pathways that interact with ICP0 to promote HSV-1 gene expression.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Herpes simplex virus 1; High-throughput assay; Infected cell protein 0

Mesh:

Substances:

Year:  2021        PMID: 34384824      PMCID: PMC8686521          DOI: 10.1016/j.antiviral.2021.105160

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   10.103


  43 in total

1.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays.

Authors: 
Journal:  J Biomol Screen       Date:  1999

2.  Antiviral activity of metabolites of T-2 toxin against herpes simplex virus type 2.

Authors:  K Okazaki; T Yoshizawa; S Kimura
Journal:  Biosci Biotechnol Biochem       Date:  1992-03       Impact factor: 2.043

Review 3.  Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management.

Authors:  Jocelyne Piret; Guy Boivin
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

4.  Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant.

Authors:  D J Goldstein; S K Weller
Journal:  J Virol       Date:  1988-01       Impact factor: 5.103

5.  Infection of a human hepatoma cell line by hepatitis B virus.

Authors:  Philippe Gripon; Sylvie Rumin; Stephan Urban; Jacques Le Seyec; Denise Glaise; Isabelle Cannie; Claire Guyomard; Josette Lucas; Christian Trepo; Christiane Guguen-Guillouzo
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-13       Impact factor: 11.205

6.  Roscovitine, a specific inhibitor of cellular cyclin-dependent kinases, inhibits herpes simplex virus DNA synthesis in the presence of viral early proteins.

Authors:  L M Schang; A Rosenberg; P A Schaffer
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

7.  The herpes simplex virus type 1 alpha protein ICP27 can act as a trans-repressor or a trans-activator in combination with ICP4 and ICP0.

Authors:  R E Sekulovich; K Leary; R M Sandri-Goldin
Journal:  J Virol       Date:  1988-12       Impact factor: 5.103

Review 8.  Update on emerging antivirals for the management of herpes simplex virus infections: a patenting perspective.

Authors:  Aswani D Vadlapudi; Ramya K Vadlapatla; Ashim K Mitra
Journal:  Recent Pat Antiinfect Drug Discov       Date:  2013-04

9.  HSV-1 ICP0: paving the way for viral replication.

Authors:  Miles C Smith; Chris Boutell; David J Davido
Journal:  Future Virol       Date:  2011-04       Impact factor: 1.831

10.  Promyelocytic leukemia protein (PML) and Daxx participate in a novel nuclear pathway for apoptosis.

Authors:  S Zhong; P Salomoni; S Ronchetti; A Guo; D Ruggero; P P Pandolfi
Journal:  J Exp Med       Date:  2000-02-21       Impact factor: 14.307

View more
  2 in total

1.  Pseudorabies Virus ICP0 Abolishes Tumor Necrosis Factor Alpha-Induced NF-κB Activation by Degrading P65.

Authors:  Xiangbo Zhang; Jingying Xie; Ming Gao; Zhenfang Yan; Lei Chen; Suocheng Wei; Ruofei Feng
Journal:  Viruses       Date:  2022-05-02       Impact factor: 5.818

2.  Population Pharmacokinetics of Intravenous Acyclovir in Oncologic Pediatric Patients.

Authors:  Natalia Maximova; Daniela Nisticò; Giacomo Luci; Roberto Simeone; Elisa Piscianz; Ludovica Segat; Egidio Barbi; Antonello Di Paolo
Journal:  Front Pharmacol       Date:  2022-04-14       Impact factor: 5.988

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.